Knee Osteoarthritis Pipeline 2025: Detailed Clinical Trials and FDA-Approved Therapies Review by DelveInsight | Merck KGaA, Peptinov, LG Chem, Akan Bioscience, BioTissue,Inc., Eupraxia Pharmaceuticals Inc., OliPass Corporation, Bone Therapeutics, Techfiel

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Knee Osteoarthritis pipeline constitutes 50+ key companies continuously working towards developing 60+ Knee Osteoarthritis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Knee Osteoarthritis Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Knee Osteoarthritis Market.

The Knee Osteoarthritis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Knee Osteoarthritis Pipeline Report:
https://www.delveinsight.com/sample-request/knee-osteoarthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Knee Osteoarthritis treatment therapies with a considerable amount of success over the years.
• Knee Osteoarthritis companies working in the treatment market are Merck KGaA, Peptinov, LG Chem, Akan Bioscience, BioTissue,Inc., Eupraxia Pharmaceuticals Inc., OliPass Corporation, Bone Therapeutics, Techfields Pharma, Biosplice Therapeutics, and others, are developing therapies for the Knee Osteoarthritis treatment
• Emerging Knee Osteoarthritis therapies in the different phases of clinical trials are- M6495, PPV 06, LG00034053, StroMel, TTAX03, EP-104IAR, OLP 1002, JTA-004, X 0002, Lorecivivint, and others are expected to have a significant impact on the Knee Osteoarthritis market in the coming years.
• In April 2025, Pacira BioSciences has revealed that its gene therapy candidate, PCRX-201 (enekinragene inzadenovec), showed lasting improvements in knee pain, function, and stiffness for up to two years in individuals with different severities of knee osteoarthritis, as demonstrated in a Phase I trial. The trial, involving 72 participants aged 30 to 80, included a single local administration of the therapy and stratified subjects based on the severity of their condition using the Kellgren-Lawrence (K/L) scale.
• In March 2025, 4Moving Biotech (4MB), a spin-off from 4P-Pharma focused on developing first-in-class treatments that alter the natural progression of knee osteoarthritis, has received approval from Health Canada to initiate the Phase 2a INFLAM MOTION "Proof-of-Concept" study for 4P004 in patients with knee osteoarthritis. This Phase 2a multicenter, randomized, double-blind, placebo-controlled trial is being conducted across the EU, US, and Canada, with three sites in Canada. The study plans to enroll 129 patients to assess, for the first time, the efficacy of 4P004 in treating knee osteoarthritis.
• In March 2025, RION, a clinical-stage regenerative medicine company specializing in exosome-based therapeutics, has announced the enrollment of its first patient in a Phase 1b clinical study to evaluate Purified Exosome ProductTM (PEPTM) for treating Knee Osteoarthritis (OA). This milestone underscores RION's dedication to advancing innovative regenerative treatments that address significant unmet medical needs.
• In March 2025, Enlivex Therapeutics, based in Israel, has finished enrolling all participants in the Phase II stage of its Phase I/II trial for Allocetra, an off-the-shelf cell therapy targeting moderate to severe knee osteoarthritis. Over 133 subjects were randomized and treated in this phase. The trial is divided into two stages, with the initial Phase I stage being an open-label, dose-escalation phase that assessed the safety and tolerability of knee injections with the cell therapy.
• In September 2024, RION, a leader in exosome innovation and therapeutic applications, has officially launched a Phase 1b study to evaluate the efficacy and safety of its exclusive Purified Exosome ProductTM (PEPTM) as a regenerative treatment for knee osteoarthritis (Knee OA)
• In September 2024, Cytonics announced the completion of subject enrollment for its Phase I clinical trial of CYT-108, a potential disease-modifying therapy for knee osteoarthritis (OA). CYT-108 is a recombinant variant of the alpha-2-macroglobulin blood serum protease inhibitor. The company initiated this Phase I trial in July, which is a first-in-human, multicenter, six-month, double-blind, randomized controlled trial (RCT) aimed at evaluating the safety and efficacy of CYT-108 in patients with unilateral, mild-to-moderate primary OA of the knee.
• In June 2024, Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage company focused on macrophage reprogramming immunotherapy, announced a positive interim data update from a Phase I/II investigator-initiated clinical trial of AllocetraTM in patients with end-stage knee osteoarthritis who were candidates for knee replacement surgery.

Knee Osteoarthritis Overview
Knee osteoarthritis is a degenerative joint disease where the cartilage in the knee gradually wears down, leading to pain, stiffness, swelling, and reduced mobility. It commonly affects older adults and can be caused by aging, joint injury, obesity, or genetics. As the protective cartilage erodes, bones may rub together, causing further damage. Treatment includes physical therapy, medications, lifestyle changes, and in severe cases, knee replacement surgery.

Get a Free Sample PDF Report to know more about Knee Osteoarthritis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/knee-osteoarthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Knee Osteoarthritis Drugs Under Different Phases of Clinical Development Include:
• M6495: Merck KGaA
• PPV 06: Peptinov
• LG00034053: LG Chem
• StroMel: Akan Bioscience
• TTAX03: BioTissue,Inc.
• EP-104IAR: Eupraxia Pharmaceuticals Inc.
• OLP 1002: OliPass Corporation
• JTA-004: Bone Therapeutics
• X 0002: Techfields Pharma
• Lorecivivint: Biosplice Therapeutics

Knee Osteoarthritis Route of Administration
Knee Osteoarthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Knee Osteoarthritis Molecule Type
Knee Osteoarthritis Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Knee Osteoarthritis Pipeline Therapeutics Assessment
• Knee Osteoarthritis Assessment by Product Type
• Knee Osteoarthritis By Stage and Product Type
• Knee Osteoarthritis Assessment by Route of Administration
• Knee Osteoarthritis By Stage and Route of Administration
• Knee Osteoarthritis Assessment by Molecule Type
• Knee Osteoarthritis by Stage and Molecule Type

DelveInsight's Knee Osteoarthritis Report covers around 40+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Knee Osteoarthritis product details are provided in the report. Download the Knee Osteoarthritis pipeline report to learn more about the emerging Knee Osteoarthritis therapies at:
https://www.delveinsight.com/sample-request/knee-osteoarthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Knee Osteoarthritis Therapeutics Market include:
Key companies developing therapies for Knee Osteoarthritis are - Eli Lilly and Company, Nature Cell Co. Ltd., Novo Nordisk A/S, Flexion Therapeutics, Inc., Grünenthal GmbH, Tissue Tech Inc., Kolon TissueGene, Inc., Bioventus LLC, Akan Biosciences, LLC, Genascence Corporation, Immunis, Inc., Novartis, Biosplice Therapeutics, Sorrento Therapeutics, Inc., Novartis, Celltex Therapeutics Corporation, MiMedx Group, Inc., Rho, Inc., Techfields Pharma Co. Ltd, Saol Therapeutics Inc, Centrexion Therapeutics, Taiwan Liposome Company, MiMedx, Ampio Pharmaceuticals, ReNu, Medipost, and others.

Knee Osteoarthritis Pipeline Analysis:
The Knee Osteoarthritis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Knee Osteoarthritis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Knee Osteoarthritis Treatment.
• Knee Osteoarthritis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Knee Osteoarthritis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Knee Osteoarthritis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Knee Osteoarthritis drugs and therapies-
https://www.delveinsight.com/sample-request/knee-osteoarthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Knee Osteoarthritis Pipeline Market Drivers
• Increase in prevalence of Osteoarthritis, robust Knee Osteoarthritis Pipeline are some of the important factors that are fueling the Knee Osteoarthritis Market.

Knee Osteoarthritis Pipeline Market Barriers
• However, risk of adverse cardiovascular events associated with the use of NSAIDs in osteoarthritis treatment, high cost associated with the treatment and other factors are creating obstacles in the Knee Osteoarthritis Market growth.

Scope of Knee Osteoarthritis Pipeline Drug Insight
• Coverage: Global
• Key Knee Osteoarthritis Companies: Merck KGaA, Peptinov, LG Chem, Akan Bioscience, BioTissue,Inc., Eupraxia Pharmaceuticals Inc., OliPass Corporation, Bone Therapeutics, Techfields Pharma, Biosplice Therapeutics, and others
• Key Knee Osteoarthritis Therapies: M6495, PPV 06, LG00034053, StroMel, TTAX03, EP-104IAR, OLP 1002, JTA-004, X 0002, Lorecivivint, and others
• Knee Osteoarthritis Therapeutic Assessment: Knee Osteoarthritis current marketed and Knee Osteoarthritis emerging therapies
• Knee Osteoarthritis Market Dynamics: Knee Osteoarthritis market drivers and Knee Osteoarthritis market barriers

Request for Sample PDF Report for Knee Osteoarthritis Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/knee-osteoarthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Knee Osteoarthritis Report Introduction
2. Knee Osteoarthritis Executive Summary
3. Knee Osteoarthritis Overview
4. Knee Osteoarthritis- Analytical Perspective In-depth Commercial Assessment
5. Knee Osteoarthritis Pipeline Therapeutics
6. Knee Osteoarthritis Late Stage Products (Phase II/III)
7. Knee Osteoarthritis Mid Stage Products (Phase II)
8. Knee Osteoarthritis Early Stage Products (Phase I)
9. Knee Osteoarthritis Preclinical Stage Products
10. Knee Osteoarthritis Therapeutics Assessment
11. Knee Osteoarthritis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Knee Osteoarthritis Key Companies
14. Knee Osteoarthritis Key Products
15. Knee Osteoarthritis Unmet Needs
16 . Knee Osteoarthritis Market Drivers and Barriers
17. Knee Osteoarthritis Future Perspectives and Conclusion
18. Knee Osteoarthritis Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Knee Osteoarthritis Market https://www.delveinsight.com/report-store/knee-osteoarthritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Knee Osteoarthritis Market Insights, Epidemiology, and Market Forecast-2034' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom).

Latest Reports Offered By DelveInsight:
• Indwelling Catheters Market: https://www.delveinsight.com/report-store/indwelling-catheters-market
• Hyperlipidemia Market: https://www.delveinsight.com/report-store/hyperlipidemia-market
• Inflammatory Bowel Disease Market: https://www.delveinsight.com/report-store/crohns-disease-cd-market
• Post Menopausal Osteoporosis Market: https://www.delveinsight.com/report-store/post-menopausal-osteoporosis-pipeline-insight
• HiPost Menopausal Osteoporosis Market: https://www.delveinsight.com/report-store/post-menopausal-osteoporosis-pipeline-insight
• Hip Replacement Devices Market: https://www.delveinsight.com/report-store/hip-reconstruction-devices-market
• Amblyopia Market: https://www.delveinsight.com/report-store/amblyopia-market
• Type 2 Diabetes Market: https://www.delveinsight.com/report-store/diabetes-market

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.